<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418584</url>
  </required_header>
  <id_info>
    <org_study_id>XHD2017</org_study_id>
    <nct_id>NCT03418584</nct_id>
  </id_info>
  <brief_title>Application of hybridAPC in the Treatment of Barrett</brief_title>
  <official_title>Application of hybridAPC in the Treatment of Barrett: a Multicenter, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the new technique of
      HybridAPC in the treatment of Barrett.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After thermal ablation of Barrett's esophagus, stricture formation is reported in 5 to over
      10% of patients. Submucosal fluid injection prior to ablation may lower the risk of stricture
      formation. The new technique of HybridAPC which combines submucosal injection with APC is
      considered to reduce the complication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2017</start_date>
  <completion_date type="Anticipated">December 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>radical rate</measure>
    <time_frame>3 months</time_frame>
    <description>Radical rate was defined as it that after 3 months of treatment, the primary lesion area returning to normal is reconfirmed by pathological diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrence was defined as it that after 3 months of treatment, Barrett's esophagus is reconfirmed by pathological diagnosis in the primary lesion again.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse event was defined as any device treatment-related adverse event such as bleeding and perforation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation time</measure>
    <time_frame>1 day</time_frame>
    <description>Operation time was defined as the time from the beginning of submucosal injection to the final end of ablation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>HybridAPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient with Barrett's esophagus is treatment by HybridAPC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HybridAPC</intervention_name>
    <description>HybridAPC is a device which combines submucosal fluid injection with APC</description>
    <arm_group_label>HybridAPC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients age is from 18 to 70.

          2. Patients who were diagnosed with Barrett's esophagus.

          3. Informed consent.

        Exclusion Criteria:

          1. Patient with severe cardiopulmonary dysfunction is unable to tolerated by endoscopy.

          2. Severe bleeding tendency.

          3. Poor compliance.

          4. Patient is very ill and life expectancy is less than 2 years.

          5. Esophageal varices or venous aneurysms, and no effective prevention or treatment for
             bleeding.

          6. Severe esophageal stenosis.

          7. Pregnancy.

          8. Lesion is located in esophageal diverticulum or spread their diverticulum.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoshen Li, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Wang, M.D</last_name>
    <phone>8613816758802</phone>
    <email>dongwang0901@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhijie Wang, M.D</last_name>
    <phone>8613816758802</phone>
    <email>wangzhijie0708@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastroenterology, Changhai Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Wang, MD</last_name>
      <phone>008613816758802</phone>
      <email>dongwang0901@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O'Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, Moayyedi P, Lyratzopoulos G, de Caestecker J; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014 Jan;63(1):7-42. doi: 10.1136/gutjnl-2013-305372. Epub 2013 Oct 28.</citation>
    <PMID>24165758</PMID>
  </results_reference>
  <results_reference>
    <citation>Manner H, May A, Kouti I, Pech O, Vieth M, Ell C. Efficacy and safety of Hybrid-APC for the ablation of Barrett's esophagus. Surg Endosc. 2016 Apr;30(4):1364-70. doi: 10.1007/s00464-015-4336-1. Epub 2015 Jun 24. Erratum in: Surg Endosc. 2016 Apr;30(4):1371.</citation>
    <PMID>26104794</PMID>
  </results_reference>
  <results_reference>
    <citation>Manner H, Neugebauer A, Scharpf M, Braun K, May A, Ell C, Fend F, Enderle MD. The tissue effect of argon-plasma coagulation with prior submucosal injection (Hybrid-APC) versus standard APC: A randomized ex-vivo study. United European Gastroenterol J. 2014 Oct;2(5):383-90. doi: 10.1177/2050640614544315.</citation>
    <PMID>25360316</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujishiro M, Kodashima S, Ono S, Goto O, Yamamichi N, Yahagi N, Kashimura K, Matsuura T, Iguchi M, Oka M, Ichinose M, Omata M. Submucosal Injection of Normal Saline can Prevent Unexpected Deep Thermal Injury of Argon Plasma Coagulation in the in vivo Porcine Stomach. Gut Liver. 2008 Sep;2(2):95-8. doi: 10.5009/gnl.2008.2.2.95. Epub 2008 Sep 30.</citation>
    <PMID>20485617</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujishiro M, Yahagi N, Nakamura M, Kakushima N, Kodashima S, Ono S, Kobayashi K, Hashimoto T, Yamamichi N, Tateishi A, Shimizu Y, Oka M, Ichinose M, Omata M. Submucosal injection of normal saline may prevent tissue damage from argon plasma coagulation: an experimental study using resected porcine esophagus, stomach, and colon. Surg Laparosc Endosc Percutan Tech. 2006 Oct;16(5):307-11.</citation>
    <PMID>17057569</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoshen Li</investigator_full_name>
    <investigator_title>Director of Gastroenterology Dept</investigator_title>
  </responsible_party>
  <keyword>argon plasma coagulation</keyword>
  <keyword>submucosal injection</keyword>
  <keyword>Barrett Esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

